ONCS News and Press, OncoSec Medical Incorporated From 11/09/20

OncoSec Medical (ONCS) announces new positive interim data from its KEYNOTE-695 Phase 2b trial evaluating TAVO (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with Merck's (MRK) KEYTRUDA (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistan...

OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020 -- 30% overall response rate (ORR) and 6% complete response (CR) rate achieved -- -- 35% ORR achieved in patients with Stage IV M1c or M1d disea...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

OncoSec Hosting an Investor and Analyst Day Webinar Showcasing Positive KEYNOTE-695 Data in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma PR Newswire PENNINGTON, N.J. and SAN DIEGO, Nov. 5, 2020 PENNINGTON, N.J. and SAN DIEGO , Nov. 5, 2020 /PRNewsw...

OncoSec to Present Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020 -- KEYNOTE-695 abstract selected to be featured for discussion led by Dr. Adil Daud during Virtual Poster Walk -- -- Company Symposium featurin...

OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19 -- First next-generation DNA vaccine candidate to deliver spike (S) protein from SARS-CoV-2 plus immune-stimulating interleukin-12 (IL-12) t...

OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer PR Newswire PENNINGTON, N.J. and SAN DIEGO, Oct. 12, 2020 PENNINGTON, N.J. and SAN DIEGO , Oct. 12, 2020 /PRNewswire/ -- OncoSec Medical Incor...

The USPTO has issued a new patent to OncoSec Medical (ONCS) covering its interleukin-12 (IL-12) based immunotherapy platform, including lead product candidate TAVO, and its proprietary EP gene delivery system.U.S. Patent No. 10,792,375, entitled Method for the Treatment of Malignancies, cover...

OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO™ and Its Gene Delivery Platform Patent Broadens Core Intellectual Property for the Intratumoral Delivery of Stimulatory Interleukins Using OncoSec's Proprietary Electroporation (EP) Technology Platfo...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...